This article discusses recent studies on the success of azacitidine (Vidaza®) treatment in reducing transfusion dependency, and increasing overall survival in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients.
Data presented at the 14th Congress of the European Society of Hematology demonstrate that treatment with azacitidine (Vidaza®) significantly extends overall survival and helps patients with myelodysplastic syndromes (MDS) become or remain red blood cell transfusion independent. Patients who benefited included those with higher-risk MDS or acute myeloid leukaemia (AML) with 20-30% blasts, as defined by the World Health Organization (WHO).
“The presentations at EHA this year continue to support the clinical benefit associated with Vidaza in MDS, including significantly extended overall survival…
Read the full article at ecancermedicalscience.com.